Thus it will be more of interest to investigate if bone marrow of pre-B ALL patients with minimal residual disease have different levels of extracellular Galectin-3 compared to those who have no detectable residual ALL cells. The gene discussed is LGALS3; the disease is acute lymphoblastic leukemia.